S. Berardi Vilei

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

E. Kimby, M. Ghielmini, H. Hawle, 2019, Blood.

An in vivo study of a growth-factor enhanced, cell free, two-layered collagen-tricalcium phosphate in deep osteochondral defects.

W. Richter, P. Mainil-Varlet, T. Gotterbarm, 2006, Biomaterials.

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

T. Pabst, E. Zucca, N. Fischer, 2013, Annals of Hematology.

Y90‐Ibritumomab tiuxetan (Y90‐IT) and high‐dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05)

M. Ghielmini, S. Rondeau, T. Pabst, 2017, Hematological oncology.

Complete subchondral bone defect regeneration with a tricalcium phosphate collagen implant and osteoinductive growth factors: a randomized controlled study in Göttingen minipigs.

W. Richter, J. Wiltfang, T. Gotterbarm, 2014, Journal of biomedical materials research. Part B, Applied biomaterials.

Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08

S. Rondeau, T. Pabst, E. Zucca, 2016, British journal of haematology.